SCHEMBL14837327

SCHEMBL14837327

COc1cc(Nc2ncc(F)c(Nc3ccc4c(c3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 16/20 0.74
EGFR P00533 3/20 0.74
JAK1 P23458 3/20 0.74
JAK3 P52333 3/20 0.74
JAK2 O60674 3/20 0.74
ADORA3 P0DMS8 2/20 0.74
TYRO3 Q06418 2/20 0.74
PLK4 O00444 2/20 0.74
AURKA O14965 2/20 0.74
STK16 O75716 2/20 0.74
RET P07949 2/20 0.74
FLT3 P36888 2/20 0.74
MAPK8 P45983 2/20 0.74
MAPK9 P45984 2/20 0.74
MST1R Q04912 2/20 0.74
PTK2 Q05397 2/20 0.74
TNK1 Q13470 2/20 0.74
IKBKE Q14164 2/20 0.74
MAP3K11 Q16584 2/20 0.74
ADCK1 Q86TW2 2/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1380946 0.94 SYK (0.67) SYKEGFRJAK1JAK3JAK2
SCHEMBL1197041 0.92 SYK (0.65) SYKEGFRJAK1JAK3JAK2
SCHEMBL2103919 0.90 SYK (0.66) SYKEGFRJAK1JAK3JAK2
SCHEMBL13007744 0.90 SYK (0.60) SYKEGFRJAK1JAK3JAK2
SCHEMBL2103278 0.89 SYK (0.69) SYKEGFRJAK1JAK3JAK2
SCHEMBL2102713 0.89 SYK (0.66) SYKEGFRJAK1JAK3JAK2
Hydrochloric Acid SCHEMBL2100858 0.89 SYK (0.68) SYKEGFRJAK1JAK3JAK2
SCHEMBL2102943 0.88 SYK (0.62) SYKEGFRJAK1JAK3JAK2
SCHEMBL2105664 0.87 SYK (0.73) SYKEGFRJAK1JAK3JAK2
SCHEMBL4002240 0.87 SYK (0.61) SYKEGFRJAK1JAK3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656372-B1 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR USE IN THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES RIGEL PHARMACEUTICALS INC (US) 2013-04-10 EP claimed
EP-3700516-B1 INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION SONIC MASTER LTD (VG) 2024-01-24 EP disclosed
US-11065243-B2 Inhibitors of DUX4 induction for regulation of muscle function SONIC MASTER LIMITED (VG) 2021-07-20 US disclosed
US-20200330452-A1 Inhibitors of Dux4 Induction for Regulation of Muscle Function SONIC MASTER LIMITED (VG) 2020-10-22 US disclosed
EP-1656372-B1 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR USE IN THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES RIGEL PHARMACEUTICALS INC (US) 2013-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200330452-A1 Inhibitors of Dux4 Induction for Regulation of Muscle Function MUSK, MERTK, PRKDC SYK 7/4885EGFR 637/4885JAK1 297/4885
US-11065243-B2 Inhibitors of DUX4 induction for regulation of muscle function MUSK, MERTK, PRKDC SYK 7/4885EGFR 637/4885JAK1 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.